Inozyme Pharma, Inc. (INZY) NASDAQ

Currency In USD

Inozyme Pharma, Inc.

Address

321 Summer Street

Boston, MA 02210

United States of America (the)

Phone

857 330 4340

Website

https://www.inozyme.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

July 24, 2020

Key Executives

Name	Title	Pay	Year Born
Douglas A. Treco	Chief Executive Officer & Chairman	552,017	1958
Axel Bolte	Co-Founder, Senior Advisor & Director	40,893	1972
Stephen J. Di Palma	Consultant	466,897	1959
Matthew Winton	Senior Vice President & Chief Operating Officer	602,100	1978
Sanjay S. Subramanian	Chief Financial Officer, Head of Business Development, Principal Accounting Officer & Corporate Secretary	607,383	1976
Petra Duda	Chief Medical Officer	0	N/A
Kurt C. Gunter	Senior Vice President & Chief Medical Officer	0	1955
Soojin Kim	Senior Vice President & Chief Technical Operations Officer	0	N/A
Yves Sabbagh	Senior Vice President, Chief Scientific Officer & Chair of the Scientific Advisory Board	0	N/A
Stefan Riley	Director of Investor Relations	0	N/A
Gayle Gironda	Senior Vice President & Chief People Officer	0	N/A
Demetrios Braddock	Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer	0	N/A

Description

Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis. Inozyme maintains a licensing arrangement with Yale University concerning particular therapeutic and preventative agents. Established in 2015, the firm's main offices are situated in Boston, Massachusetts.